PROM1 and neoplasm: Following one passage through NOD-SCID mice, CD133-/CD26+ expression was significantly increased, rising from 13.7% (±1.8%) in the original tumor tissue, to 29.4% (±3.8%) in xenograft tissue (Fig. 5B).